Cognition-enhancing Effects of Donepezil in Traumatic Brain Injury
Overview
Affiliations
The purpose of this study was to investigate the effects of donepezil, a cholinergic agent, on chronic cognitive impairment due to traumatic brain injury (TBI). Chronic patients underwent two standardized neuropsychological evaluations--one before and the other 3 months following treatment with donepezil. Together with global inventories that appraised behaviour, fatigue, anxiety and depression, these evaluations also assessed executive functioning, memory and attention. Of the 10 patients who followed the therapy, 8 reported subjective improvement in at least one cognitive domain following therapy and most of them reported better functioning in everyday activities. This effect was supported by a slight global improvement when considering the global score of the different affectivo-behavioural scales. At the neuropsychological level, although we could observe a slight improvement in the majority of the considered tests, significant positive changes were mainly found in tests assessing speed of processing, learning and divided attention. These findings suggest that donepezil may lead to better general functioning and improve attentional skills in patients with chronic TBI.
Youn D, Lee Y, Han S, Kim J, Jung H, Han G Life (Basel). 2024; 14(7).
PMID: 39063593 PMC: 11278464. DOI: 10.3390/life14070839.
Miller A, Evanson N, Taylor J Neural Regen Res. 2023; 19(8):1686-1695.
PMID: 38103232 PMC: 10960296. DOI: 10.4103/1673-5374.389628.
Fitzgerald P, Hale P, Ghimire A, Watson B Transl Psychiatry. 2020; 10(1):255.
PMID: 32712627 PMC: 7382650. DOI: 10.1038/s41398-020-00928-w.
Feasibility and effects of galantamine on cognition in humans with cannabis use disorder.
Sugarman D, Aquino J, Poling J, Sofuoglu M Pharmacol Biochem Behav. 2019; 181:86-92.
PMID: 31082417 PMC: 6545124. DOI: 10.1016/j.pbb.2019.05.004.
Njoku I, Radabaugh H, Nicholas M, Kutash L, ONeil D, Marshall I Exp Neurol. 2019; 315:32-41.
PMID: 30711647 PMC: 6534164. DOI: 10.1016/j.expneurol.2019.01.019.